Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001213900-25-003853·Cadrenal Therapeutics, Inc.
Schedule 13G ownership disclosure
Cadrenal Therapeutics Inc
Common Stock, $0.001 par value per share · CUSIP: 127636207
Event date: 2024-12-31
- Filing-level shares
- 53,205.00
- Percent of class
- 2.96%
- John Raymond Murphy
Shares: 53,205.00 · Class: 2.96%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-003853
- Form type
- SCHEDULE 13G/A
- Filer
- Cadrenal Therapeutics, Inc.
- CIK
- CIK 1937993
- Filed
- Jan 15, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership